An experimental pain-relieving drug delivery method for farm animals using microneedle patches may not have delivered an ...

In the study, a once-daily, single-tablet combination of bictegravir and lenacapavir was as effective as Gilead's existing ...

A new scale for grading ocular adverse events in oncology trials addresses ambiguities in CTCAE version 5 and includes dose modification recommendations. The scale, implemented in the I-SPY 2 trial, ...

Discovering effective drug combinations may now be easier thanks to a screening platform made public today by St. Jude ...

Sanofi drug faces FDA delay following a failed late-stage trial for multiple sclerosis, with regulatory guidance expected by Q1 2024.

Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor, sending its shares up 25% in morning trade.

Sanofi flagged a second delay to an FDA decision for its experimental multiple sclerosis drug and reported disappointing ...

Shares in argenx fell after the pharmaceutical company said it would stop late-stage trials for an experimental drug to treat thyroid eye disease due to lack of efficacy. In European afternoon trading ...

Dec 15 () - Shares of French pharmaceutical group Sanofi fell 4% on Monday after it flagged another delay to ​a U. regulatory ...

Sanofi shares slide after FDA delays review of its MS drug tolebrutinib and a late-stage trial fails to meet its main goal.

Immunome said on Monday its experimental drug ‍met the main goal in a late-stage study for patients with a rare type ‌of tumor. The oral ‌drug, varegacestat, is being tested in patients with desmoid ...

Argenx SE shares fell the most in seven months after the biotech firm said it will discontinue late-stage trials for an experimental medicine to treat an autoimmune disease affecting the eyes.